Clinical Trial Update: ImmunoPET With an Anti-CD8 Imaging Agent [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial assessing an anti-CD8 immunoPET imaging agent for metastatic cancer and unresectable malignant neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Unresectable Malignant Neoplasm

Drugs mentioned

• Anti-CD8 ImmunoPET Imaging Agent (CD8-targeted immunoPET tracer)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Metastatic Cancer, Unresectable Malignant Neoplasm | Phase 1, Phase 2 | Status: UNKNOWN